The use of albumin solid dispersion to enhance the solubility of unionisable drugs by Khoder, Mouhamad et al.
This is an Accepted Manuscript of an article published by Taylor & Francis in Pharmaceutical 
Development and Technology on 24/08/17, available online: 
http://www.tandfonline.com/doi/full/10.1080/10837450.2017.1364267?needAccess=true  
  
The Use of Albumin Solid Dispersion to Enhance the Solubility of 
















a Drug Discovery, Delivery and Patient Care (DDDPC) Theme, School of Life Sciences, 
Pharmacy and Chemistry, Kingston University London, Kingston Upon Thames, United 
Kingdom. 
b Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt. 
c Institute of Chemistry of Poitiers : Materials and Natural Resources,  Catalysis and 
unconventional media's Team University of Poitiers, France 
 
d Faculty of Medical Science, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 
1SQ, United Kingdom 
 
e School of Pharmacy, The University of Auckland, Auckland, New Zealand 
 
*Corresponding author 
Mouhamad Khoder, Ph.D. 
Drug Discovery, Delivery and Patient Care (DDDPC) Theme,  
School of Life Sciences, Pharmacy and Chemistry,  
Kingston University London, Penrhyn Road,  
Kingston Upon Thames, Surrey KT1 2EE, UK,  
Tel +44 20 8417 9000  
e-mail: m.khoder@kingston.ac.uk,  
            mouhamad.khoder@gmail.com 
The use of albumin solid dispersion for enhanced un-ionisable drugs 
solubility 
In this study, solid dispersions of prednisolone (PRD) and bovine serum albumin 
(BSA) were prepared by spray drying and freeze drying methods using a  PRD:BSA 
solution (20:1 Molar Ratio (MR)). PRD-BSA dispersed mixtures were characterised by 
scanning electron microscopy (SEM), and powder X-ray diffraction (XRD), and 
differential scanning calorimetry (DSC). PRD-BSA physical and dispersed mixtures 
showed significantly higher solubility in water than that of unprocessed drug. 
Enhancement factor of six was obtained in both physical mixture and solid dispersion 
solubility studies. In-vitro dissolution and release studies under physiological 
conditions showed an immediate release of PRD from the solid dispersions, with 
almost 90% of the drug dissolved in the first 10 min. PRD was immediately released 
from BSA binding complex. This study demonstrates the potential for the use of BSA 
to enhance the solubility and dissolution rate, hence bioavailability, of the unionisable 
drugs. 




The recent drug discovery techniques have led to an increasing number of drugs that are 
poorly soluble in water. It is estimated that 40 % of the approved drugs and almost 90% of 
drugs candidates are poorly soluble (Kalepu and Nekkanti 2015). For this reason, the 
development of new strategies to enhance drug solubility remains one of the major research 
areas in drug discovery and development process (Bellantone 2014, Bosselmann and 
Williams 2012). An approach to enhance the solubility of ionisable drugs is by adjusting the 
pH of the solvent or by forming soluble salts (Kalepu and Nekkanti 2015, Owen 2013, 
Serajuddin 2007). Howover, the pH has less pronounced impact on the solubility of the un-
ionisable drugs; consequently, they are insoluble in various parts of GIT. Therefore, 
enhancing the solubility of this drug category is considered more challenging (Bellantone 
2014, Bosselmann and Williams 2012). Several approaches have been developed to enhance 
unionisable drugs solubility including, but not limited to, size reducing approach, particle 
engineering, micellization, and cyclodextrins and polymers complexation (Cavallari et al. 
2005, Chen et al. 2011, Del Valle 2004, Junghanns and Müller 2008, Strickley 2004).  
In a recently published work, we have described the use of albumin as solubility enhancer of 
ionisable drugs using indomethacin as drug model. An enhancement factor of 100,000 was 
obtained after formulating indomethacin in BSA solid dispersions. The solubility enactment 
of indomethacin in presence of BSA is thought to be mainly due to the formation of salt 
bridges between the drug and the albumin molecules (Khoder et al. 2016). However, the 
solubilizing properties of albumin are not limited to its ability to form salts with ionisable 
molecules but also to its remarkable ability to form reversible binding complexes with 
hydrophobic drugs (Ghuman et al. 2005, Urien et al. 2007). Indeed, albumin displays two 
main sites that bind the ligands mainly by hydrophobic and electrostatic interactions.  Several 
secondary binding sites are also available that increase the number of bound molecules 
(Evans 2002). The hydrophobic molecules of medium size (100-600 Da) are amongst the 
substances that showed the highest affinity to albumin. The interaction forces involved in the 
binding process are mainly hydrophobic, Van der Waals force and hydrogen bonding 
interactions (Peters Jr 1995, Shi et al. 2013b, Urien, Tillement and Barré 2007).  
Bovine serum albuin (BSA) has been widely used in numerous pharmaceutical and medical 
applications thanks to its stability, biocompatibility and low immunogenicity (Elzoghby et al. 
2012, Khoder et al, 2016). The aim of this study is to investigate the potential use of the BSA 
to enhance the solubility of the unionisable drugs using PRD as a model drug. Prepared by 
freeze drying and spray drying techniques, PRD-BSA solid dispersions are characterised by 
SEM, XRD, and DSC. PRD solubility is evaluated in water in the presence of increased 
amounts of BSA. In addition, the dissolution rates and release profiles are established under 
physiological conditions. 
Materials and Methods 
Materials 
PRD was provided by Acros organics (USA). BSA lyophilised powder was purchased from 
sigma-Aldrich (UK). Methanol, ethanol, trichloroacetic acid (TCAA), and all the other 
materials and reagents used in protein precipitation, analytical methods, and medium 
preparation were of analytical grade of purity and were all purchased from sigma-Aldrich 
(UK). 
Methods  
 Solid dispersions preparation  
A specified amount (0.12 g) of PRD was dissolved in 5 ml ethanol and gradually added to 
100 ml BSA solution (1% w/v). The resulting PRD-BSA hydro-alcoholic solution (20:1 
PRD:BSA MR) was frozen in liquid nitrogen and freeze-dried for 72 h using (VirTis 
BenchTop Pro, UK). Alternatively, for the preparation of spray-dried formulation, the 
resulting PRD-IND solution was spray-dried using Buchi spray dryer (Buchi, Switzerland) 
under the following conditions: feeding rate of 1 mL/min, inlet temperature of 120 °C, and 
outlet temperatures of 50-60 °C.  
The resulting PRD-BSA solid dispersions were named as showed in the table 1: 
 
[Table 1 near here] 
Differential scanning calorimetry (DSC) 
DSC thermograms of PRD, BSA, PRD:BSA physical mixture, SD-sd and FD-sd were 
obtained using differential scanning calorimeter (Mettler Toledo, DSC822e, UK). Samples 
(2-5mg) were weighed and crimp-sealed in aluminium pans with the led pierced. The samples 
were heated under nitrogen gas flow (20 mL/min) over a temperature range of 25 °C to 300 
°C and at a heating rate of 10 °C/min. The obtained thermograms were analysed using 
STAReSW 10.00 software. 
X-ray Diffractometry 
Diffraction patterns of the samples outlined above (under DSC section) were obtained using 
Bruker diffractometer (Bruker AXS D8 Advance; Bruker Corporation, Billerica, MA, USA). 
The diffractometer operated at room temperature and at 40 kV. Samples were scanned from 
from 2° to 45° 2θ at a step size of 0.1° and collected data were analysed using DIFFRAC plus 
XRD commander software (Bruker Corporation). 
Scanning electron microscopy 
The morphology of the PRD, BSA, FD-sd and SD-sd samples were examined using Zeiss 
Evo50 electron microscope (Oxford instrument, UK). Prior to imaging and in order to enable 
electricity conduction, samples were coated with a fine layer of gold using a sputter coater 
(Polaron SC500, Polaron Equipment, Watford, UK) at 20 mA for 3 min at low vacuum and in 
the presence of argon gas (Polaron Equipment, Watford, UK). The microscope was operated 
at an accelerating voltage of 30 kV under low-vacuum mode.  
Equilibrium solubility studies   
The equilibrium solubility of PRD was determined using saturation shake-flask method by 
adding an excess amount of drug (50 mg) to 1 mL distilled water containing increased 
amounts of BSA. The final concentrations of BSA were (0, 0.3, 0.6, 0.9, 1.8 and 3.6 mM). To 
assess the solubility of PRD formulated in solid dispersions, increased amount of FD-sd and 
SD-sd were added to 1 mL distilled water to produce final concentrations of BSA that were 
equal to those mentioned above. The samples were then shaken at 25 °C for 24 h to reach 
equilibrium, centrifuged for 3 min at 10,000 rpm (RCF: 12.27 × 10
4
) (Thermo Scientific, 
Germany), and the supernatants were collected and filtered through 0.45 μm Milipore filters). 
The drug concentrations in the obtained filtrates were determined using the HPLC analysis 
method as detailed below.  
Analytical method 
The chromatographic analysis was performed using PerkinElmer HPLC system (USA) which 
consisted of a degasser, a pump, an auto-sampler, and a UV detector set at 254 nm. The 
separation was carried out using a HyperClone
TM
 analytical column (4.6×150mm, C18, 5μm, 
130Å) and an isocratic mobile phase consisted of methanol (70 % v/v) and water (30 % v/v). 
The flow rate was 1.0 mL/min and the simple injection volume was 10 µl.  
BSA-free samples were adequately diluted with mobile phase and the drug concentration was 
determined using a calibration standard obtained in mobile phase. The HPLC method was 
linear in the mbile phase over a range of 7.5 µg/mL to 0.5 mg/mL with a correlation 
coefficient (r2) of 0.998. For BSA-containing samples, samples were adequately diluted with 
water to reach BSA concentration in the calibration curve (0.03 mM) and the concentration of 
drug was determined using a calibration standard prepared in BSA solution (0.03 mM). In 
BSA containing samples, the HPLC method was linear over a range of 25 µg/mL to 0.5 
mg/mL with a correlation coefficient (r2) of 0.996. Prior injection in HPLC system, PRD 
extraction from all BSA-containing samples was realised. Briefly, 0.2 mL sample was placed 
in 1.5 mL Eppendorf tube and 0.8 mL TCAA solution (10% w/v) was added and vortex-
mixed for 2 min. Samples were left for 30 min and centrifuged for 3 min at 10,000 rpm 
(RCF: 12.27 × 10
4
) (Thermo Scientific, Germany). The supernatants were filtrated using 0.45 
μm Milipore filters and diluted 5 times with the mobile phase before being injected into the 
HPLC system. The extraction recovery (%) of PRD from BSA solution was (92.16 ± 11).  
Dissolution studies and release studies 
In-vitro dissolution profiles of pure PRD, SD-sd, and FD-sd were established using USP 
dissolution apparatus 2–Paddle (CALEVA, UK). The dissolution study was conducted in 900 
ml of phosphate buffer pH 7, at 37 ± 0.5 °C using a stirring rate of 100 rpm. The powders 
(equivalent to 40 mg PRD) were dispersed in the dissolution medium and aliquots of 2 ml 
were withdrawn at 0, 5, 10, 15, 20, 30, 45, 60 min. Aliquots were filtered through 0.45 μm 
Milipore filters before being analysed using UV spectrometer (JENWAY, UK) at 254 nm.  
In order to evaluate the drug release from albumin complex, in-vitro drug release was 
performed using Franz diffusion cells (LOGAN Instruments Corp, USA). Cellulosic synthetic 
membranes (Cut-off 12 KD, Medicell Membrane Ltd, UK) were soaked in distilled water for 
24 h before being mounted between the two compartments of Franz cells. The cut-off of used 
membrane allows the diffusion of the free drug only. Receptor’s compartment was filled with 
12 mL PBS (pH 7) and was continuously homogenized using stirring magnetic bars and kept 
at 37 °C. The donner compartments were filled with 2 mL of PRD, SD-sd, and FD-sd 
aqueous solutions (0.05% w/v) and covered with Parafilm to avoid evaporation. The air 
bubbles formed underneath the membrane were removed via the side arm by carefully tilting 
the Franz cell. Serial sampling of 1 mL was performed after 0. 0.5, 1, 2, 3, 4, 5, and 6 h and 
fresh receptor liquid was added to receptor compartment to replace the buffer. The amount of 
diffused drugs was determined spectrophotometrically. As BSA molecules could not 
penetrate through the membrane pore, no extraction step was needed. The UV method was 
validate against the HPLC reported in the paper. 
Statistical analysis 
Statistical significance was determined using the one-way analysis of variance (ANOVA) and 
Student’s t-tests as appropriate. All experiments were performed in triplicate and values were 
expressed as the mean ± standard deviation. Values of P<0.05 were considered statistically 
significant. 
Results 
Solid dispersions characterisation 
The surface morphology of PRD, BSA, SD-sd and FD-sd powders was examined using 
scanning electron microscopy (Fig. 1). While PRD SEM image revealed crystals of different 
shapes and size (Fig. 1a), those of BSA showed big plate-like chunks (Fig. 1b). On the other 
hand, FD-sol powder showed ribbon-like shape without any evidence of crystallinity (Fig. 
1d). SD-sol displayed rounded microparticles with an average size ranging between 0.2 to 2 
µm and a smooth holed surface (Fig. 3c).  
 
[Figure 1 near here] 
 
Fig. 2 shows the DSC thermograms of PRD, BSA, PRD-BSA:PM, SD-sd and FD-sd. PRD 
displayed a sharp endothermic peak at 245 °C which assigned to its melting point (Couto et 
al. 2014, Huanbutta et al. 2016, Veiga et al. 1985). The same peak was also observed in the 
PRD-BSA physical mixture thermogram indicating the crystalline state of the drug. However, 
this endothermic peak disappeared completely from the thermograms of SD-sd and Fd-sd 
(Fig. 2) suggesting the dispersion of PRD in its amorphous form within the BSA matrix. 
Interestingly, a small exothermic peak was observed on the solid dispersions thermograms at 
145-150 °C that could be attributed to a partial recrystallization (polymorphic phase 
transition) of PRD under the DSC analysis conditions; the fact that might confirm the 
amorphous state of the drug (Veiga, Cadorniga and Lozana 1985).  
 
[Figure 2 near here] 
 
The solid state of PRD in the BSA matrix was also observed by XRD technique. The XRD 
pattern of raw and processed PRD and BSA are shown in Fig. 3.  
 
[Figure 3 near here] 
 
While the diffraction spectrum of BSA showed a typical pattern of amorphous structure, the 
PRD diffractogram revealed several sharp high-intensity peaks indicating its crystalline state 
(Huanbutta, Sangnim, Limmatvapirat, Nunthanid and Sriamornsak 2016, Li et al. 2007). 
Similar characteristic peaks were observed in the XRD pattern of PRD:BSA-PM (Fig. 3). 
However, those diffraction peaks disappeared completely from the XRD patterns of both 
spray-dried and freeze-dried solid dispersions (Fig. 3). These results are in a good agreement 
with those obtained with DSC.  
Solubility studies 
 
The drug solubility was firstly assessed in water in presence of increased amount of BSA. 
Fig. 4a shows the concentrations of dissolved PRD (mg/L) as a function of BSA 
concentrations (mM). The addition of increased amounts of BSA resulted in significant and 
continuous increases in PRD solubility (P<0.05). The initial solubility of PRD, in pure water, 
was around 200 mg/L, which is in correspondence with the literature (Solubility Data  2003). 
Interestingly, PRD solubility increased significantly to the range of 1000 mg/L; i.e. 
enhancement factor of about 5.34, when the BSA was added at a concentration of 3.6 mM 
(24%w/w) (Fig. 3a). The phase solubility diagram, obtained by plotting the PRD molar 
concentration against BSA molar concentration, revealed a linear relationship that is 
classified as “AL-type” (Fig. 4b). Based on the curve trend-line slope values (<1), it is 
assumed that a 1:1 stoichiometry complex was formed (Higuchi 1965, Shi, Zhu, Wang, Chen 
and Shen 2013b). The binding constant (K1:1) has been determined from the solubility 
diagram as following:  
K1:1 = slope / [S0 (1 - slope)]  
Where (S0) is drug initial solubility of the drug (Loftsson et al. 2005).  




, which is in 
accordance with the results previously reported in the literature (Frey and Frey 1984, Legler 
and Benet 1986, Rocci et al. 1982). However, in a recent study, higher association constant 




, indicating a stronger binding interaction between PRD 
and BSA (Shi, Zhu, Wang, Chen and Shen 2013b). However, PRD:BSA binding was carried 
out in TRIS buffer; this could interfere favourably in the formation of hydrogen bonds and 
yield a higher complexation extent.  
 
[Figure 4 near here] 
 
PRD solubility was then assessed after the preparation of the PRD:BSA solid dispersions. 
The solid dispersions were prepared by both freeze-draying and spray-drying techniques 
using a solution of (20:1) PRD:BSA molar ratio; 20 folds higher than the binding complex 
stoichiometry (1:1). Fig. 5 shows the dissolved amounts of PRD (mg/L) as a function of BSA 
concentrations (mM) for PRD:BSA PM, SD-sd and FD-sd. The initial solubility of freeze-
dried and spray-dried PRD, with no BSA added, was similar to that of unprocessed PRD. 
Similarly, formulating PRD in BSA solid dispersions did not lead to a significant 
enhancement in PRD solubility compared to that obtained by PRD:BSA physical mixture 
(P>0.05) (Fig 5).  
 
[Figure 5 near here] 
 
Dissolution and release studies  
 
Fig. 6a shows the dissolution profiles of PRD, SD-sd and FD-sd in phosphate buffer (pH 7) at 
37 °C. The dissolution rate of unprocessed PRD was relatively low with almost 15% and 
60% dissolved after 10 min and 1 h, respectively. On the other hand, formulating PRD in 
BSA solid dispersions allowed an instant dissolution with almost 90% dissolved within the 
first 10 minutes.  
Franz diffusion cell was used to evaluate the drug release rate from BSA complex after the 
dissolution step using phosphate buffer (pH 7) as a release medium and a semi-permeable 
membrane that allows the diffusion of the free PRD molecules only. The released amount is 
the amount of drug diffused through the cellulosic membrane to the receptor compartment. 
Fig. 6b shows that the PRD release rates from BSA complex were comparable to those 
obtained from PRD aqueous solution (P>0.05) with approximately 50% PRD diffused to the 
receptor compartment after 6h. 
 
[Figure 6 near here] 
 Discussion 
In a recent study, we demonstrated the possible use of BSA as solubility enhancer for 
indomethacin as ionisable drugs model, where the solubility was improved up to 10
5 
times 
after formulating it in BSA solid dispersion (Khoder et al, 2016). This spectacular solubility 
enhancement was mainly attributed to the formation of salts bridges between indomethacin 
carboxylate groups and BSA amino groups. In this study, we investigated the potential use of 
BSA solid dispersion approach to enhance the solubility of unionisable drugs using PRD as 
drug model. Unionisable drugs are not expected to form salts with BSA molecules, yet they 
might bind to albumin molecules and form a reversible drug-albumin binding complex of 
higher solubility (Ghuman, Zunszain, Petitpas, Bhattacharya, Otagiri and Curry 2005, Urien, 
Tillement and Barré 2007). Additionally, converting the drug into a molecular and/or 
amorphous state that is homogeneously dispersed within the hydrophilic matrix provided by 
BSA might actively contribute in the enhancement of drug solubility and dissolution rate 
(Graeser et al. 2010, Hancock and Zografi 1997, Huang and Dai 2014, Khoder et al, 2016). 
PRD:BSA solid dispersions were obtained using two different particle engineering 
technologies; spray-drying and freeze-drying. SEM, DSC, and XRD results (Fig. 1-3) 
revealed the amorphous or/and molecular state of PRD within the BSA matrix. The surface 
morphology of spray dried powder displayed rounded and smooth microparticles with a size 
ranging between 0.3 and 3 µm and a single hole at the surface (Fig.1c). The formation of this 
single indentation on particles surface could be explained by the outbreak of the skin-like 
outer shell formed on the droplet surface due to high pressure generated during the heating 
process (Khoder et al, 2016, Walzel and Furuta 2011). Unprocessed PRD displayed a poor 
solubility in water that could be attributed to its crystalline state (Fig. 1-3) and lipophilic 
properties. However, PRD aqueous solubility has been significantly and steadily enhanced by 
increasing amounts of BSA (Fig 4). PRD solubility enhancement might be explained by the 
spontaneous formation of a soluble 1:1 binding complex between PRD and BSA molecules, 
where each PRD molecule was accommodated into the hydrophobic cavity of the subdomain 
IIIA (site II) of BSA (Shi, Zhu, Wang, Chen and Shen 2013b). The interaction forces 
involved in the binding process are mainly hydrophobic, Van der Waals force and hydrogen 
bonding interactions (Shi, Zhu, Wang, Chen and Shen 2013b). The extent of PRD solubility 
enhancement directly relates to its binding affinity to BSA and the solubility of the resulting 
complex. The PRD-BSA solid dispersions were prepared by either spray-drying or freeze-
drying of a (20:1 MR) PRD:BSA solution. The aim of increasing the PRD:BSA molar ratio 
from 1:1 (the binding ratio obtained in the physical mixture) to 20:1 was to allow more 
molecular interactions between PRD and BSA to take place during the drying process and, 
thus, improve further the solubility enhancement. Formulating PRD:BSA solution into solid 
dispersions by both spray-drying and freeze-drying techniques did not result in any 
significant additional solubility enhancement compared to that obtained by the physical 
mixture study (Fig. 5). This is mainly because the complexation capacity of BSA molecule is 
limited to one PRD molecule only. This result highlights the fact that the formation of 
binding complex is the main mechanism behind the solubility enhancement of PRD. 
Furthermore, the two drying techniques used to form the solid dispersions had no impact on 
BSA stability, i.e., BSA molecules seemed to refold successfully in water to form the 
PRD:BSA complex. Compared to previous reports, the solubility enhancement achieved by 
BSA solid dispersion of PRD has found to be significantly higher than that of PVP spry-dried 
solid dispersion, similar to that of the γ-cyclodextrin solid dispersion, and lower than that 
obtained by β-cyclodexrin solid dispersion (Couto, Vieira, Florindo, Videira and Cabral-
Marques 2014, Fukuda et al. 1986, Ghuzlaan et al. 2009). However, due to its high molecular 
weight, BSA concentrations used for solubility enhancement in this study were lower than 
those of cyclodexrins. The amorphous and consistent dispersion of PRD within the 
hydrophilic matrix of BSA led to a significant enhancement in the drug dissolution (Fig 6. a) 
(Graeser, Patterson, Zeitler and Rades 2010). Besides, the formation of the molecular binding 
complex between PRD and BSA molecules might also help protect the molecular state of 
PRD in BSA matrix. Therefore, the step of drug dissolution might be bypassed, and an 
immediate solution might be obtained. Franz diffusion cell was used in this study to evaluate 
the drug release rate from BSA complex after the dissolution step. Franz diffusion cell was 
used in in this study to evaluate the drug release rate from BSA complex after the dissolution 
step. For this reason, the membrane pore size was selected in such a way that it allows the 
diffusion of the free drug only. The experiment results demonstrated that albumin molecule 
released immediately the bond molecules (Fig. 6b). Indeed, Van der Waals and hydrogen 
bonding interaction are thought to be the main intramolecular forces binding PRD to BSA 
molecules (Shi et al. 2013a). The weak nature of these intramolecular forces was reflected on 
the relatively low association constant reported in this study. The concentration gradient and 
the osmotic pressure on the both sides of the diffusion membrane are thought to be high 
enough to disassociate PRD-BSA complex and immediately release PRD molecules through 
the cellulosic membrane. This immediate release is a key factor to achieve rapid in-vivo 
absorption, hence improved bioavailability. 
Conclusion 
In this study, we demonstrated the possible use of BSA particle engineering technique to 
enhance the solubility of unionisable drugs using PRD as drug model. In physical mixture, a 
significant enhancement in PRD solubility dependent on BSA concentrations was observed. 
PRD:BSA solid dispersions prepared by both freeze-drying and spray-drying methods 
produced an enhancement in drug solubility comparable to that of physical mixture. PRD was 
found to transform into the amorphous/molecular state within the BSA hydrophilic matrix. 
This produced a significant increase in the drug dissolution rate compared to that of the free 
drug. Additionally, an immediate release of PRD from BSA binding complex was also 
reported.  
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